Expert-based drug lists to measure anticholinergic burden: similar names, different results
Article first published online: 31 MAR 2013
© 2013 The Authors. Psychogeriatrics © 2013 Japanese Psychogeriatric Society
Volume 13, Issue 1, pages 17–24, March 2013
How to Cite
LERTXUNDI, U., DOMINGO-ECHABURU, S., HERNANDEZ, R., PERAL, J. and MEDRANO, J. (2013), Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics, 13: 17–24. doi: 10.1111/j.1479-8301.2012.00418.x
- Issue published online: 31 MAR 2013
- Article first published online: 31 MAR 2013
- Received 28 November 2011; revision received 9 March 2012; accepted 21 March 2012.
- cholinergics/antagonists × adverse effects;
- drug utilization;
- observer variation
Background: Scoring scales such as the Anticholinergic Drug Scale (ADS), the Anticholinergic Risk Scale (ARS), and the Anticholinergic Cognitive Burden Scale (ACB) provide an estimation of total anticholinergic burden. Not all the lists include the same drugs, and the points given for certain drugs differ among them. Whether these discrepancies present important differences in the estimation of anticholinergic burden for an individual patient is unknown. Therefore, the aim of this study is to assess agreement among the three scales.
Method: Anticholinergic burden was measured with the three scales in 83 patients aged ≥65 years in a medium- and long-stay psychiatric hospital. Subsequently, patients were categorized into three risk categories: low risk (0 points), medium risk (1–2 points) or high risk (3 or more points). The chance-corrected measures of agreement for the different scores were determined with the k-statistic (kappa).
Results: Values for kappa were: 0.19 for Anticholinergic Risk Scale-Anticholinergic Drug Scale, 0.21 for ACB-Anticholinergic Drug Scale and 0.25 for Anticholinergic Risk Scale-ACB. The mean anticholinergic burden measured with ACB was 3.28.
Conclusions: There is poor agreement among the three scales. These lists cannot be directly applied to different settings in which drug availability differs substantially, and they require periodic updates. Anticholinergic burden in our setting (psychogeriatric inpatients) was particularly high.